A frontline chemotherapy-free strategy using a tyrosine kinase inhibitor and immunotherapy beats the conventional chemotherapy approach for treating Philadelphia-positive acute lymphoblastic leukaemia ...

Brentuximab vedotin (Adcetris, Takeda) is now on the PBS as part of the multi-drug BrECADD chemotherapy regimen for front-line treatment in adult patients with advanced stage CD30+ Hodgkin lymphoma.

JAK inhibitors should be an option for symptomatic myelofibrosis patients even if their disease is low risk, according to new guidelines from the American Society of Hematology (ASH). Published in ...

The addition of the bispecific T-cell engager tarlatamab to durvalumab as first-line maintenance therapy significantly improves survival in patients with extensive-stage small-cell lung cancer (SCLC).

A joint clinical practice guideline recommends novel peroxisome proliferator-activated receptor agonists as second-line therapy for patients with primary biliary cholangitis, along with a new therapy ...

PCOS is likely to need another rebrand in the near future because its new name, PMOS, is scientifically inaccurate, it is being argued. A debate over the future name of polycystic ovary syndrome has ...

SGLT2 inhibitor use in patients with cardiovascular disease, diabetes, heart failure, and/or chronic kidney disease is associated with small but statistically significant and consistent increases in ...

Cholesterol drug fenofibrate reduces the progression of diabetic retinopathy in patients with type 1 diabetes as well as type 2, researchers say. The LENS study randomised 305 participants with T1D ...

The image of the wise and skilful healer has driven countless clinicians to dedicate their lives to the profession, but that ...

Join an expert panel of QLD oncologists as they present their selection of transformational clinical data in breast, lung, GU, GI and skin cancers from the ESMO Congress 2026 and discuss the impacts ...

Join an expert panel of VIC oncologists in-person or watch online as they present their selection of transformational clinical data in breast, lung, GU, GI and skin cancers from the ESMO Congress 2026 ...